Once-Daily Insulin in Prefilled Pen Gets FDA Nod

Share this content:

Sanofi announced that the Food and Drug Administration (FDA) has approved once-daily Toujeo (insulin glargine [rDNA origin]) injection 300 U/mL to improve glycemic control in adults with type 1 and type 2 diabetes mellitus.

The approval of Toujeo was based on an FDA review of data from the EDITION clinical trial program that was comprised of a series of international Phase 3 studies on the safety and efficavy of Toujeo in over 3,500 adults with type 1 and type 2 diabetes. All studies met the primary study endpoints by demonstrating similar blood sugar control with once-daily Toujeo compared to once-daily Lantus (insulin glargine [rDNA origin]; Sanofi) injection 100 U/mL, including an open-label, randomized, active-control, parallel, treat-to-target studies of up to 26 weeks of duration with six months safety extension.

Toujeo will be available in the Toujeo SoloSTAR, a disposable prefilled pen with 450 units of Toujeo. It is expected to be available at the beginning of the second quarter of 2015.

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Zika, West Nile Cases Reported in Alabama

Zika, West Nile Cases Reported in Alabama

State health officials note that Zika hasn't been transmitted locally

TBI Linked to Increased Suicide Risk

TBI Linked to Increased Suicide Risk

Increased suicide risk with one, two, and three or more medical contacts for traumatic brain injury

Triple Combo Blood Pressure Pill Can Improve BP Control

Triple Combo Blood Pressure Pill Can Improve BP ...

Proportion achieving target BP increased with use of triple combo pill versus usual care at six months

is free, fast, and customized just for you!




Already a member?

Sign In Now »